Melanoma can be cured – TIL treatment For further information: הסרט הופק ע"י שלם תקשורת שלומית וייס חן This method is intended for patients in an advanced stage of metastatic melanoma who qualify for the treatment eligibility criteria. The Adoptive Immunotherapy method is based on the principle of strengthening the immune response of the patient against his own malignant cells. The treatment is based on the assumption that T Lymphocytes whose purpose is to fight the tumor and prevent its development exist within the environment of the malignant tumor, but that due to a failure of the immune system, these T lymphocytes are not active enough. The purpose of this treatment is the proliferation of the TIL cells, in such a way that they become very active in the patient's body and lead to the destruction and death of the cancer cells. This unique clinical research is currently ongoing only at the NIH in the USA, and at the Ella Institute, which has also been able to successfully implement this treatment methodology outside of the USA. Tens of patients have been successfully treated by this method at the Ella Institute - including European patients arriving for the sole purpose of receiving this treatment. Initially, the patient undergoes surgery to remove the tumor or metastasis. The tissue is taken to the laboratory in order to extract T lymphocytes (T Lymphocytes are a certain type of white blood cells), while the working hypothesis is that in the region surrounding the tumor there is a relatively high concentration of lymphocytes specialized in the recognition and destruction of melanoma cells. During the first stage, this cell population is isolated from the rest of the cells, in order to achieve a homogenous population of TIL specific cells. During the second stage, which lasts two weeks, the TIL cells are cultivated and proliferated under laboratory conditions, in the presence of substances which activate them against melanoma cells. At the end of the process, thousands of millions of cells are obtained, which are able to recognize the specific tumor of the patient, and whose purpose is to destroy the tumor. At the same time, the patient undergoes chemotherapy, in order to neutralize any biological systems which could interfere with the effective function of the TIL cells, against the melanoma cells. On the day of the treatment, the patient receives the millions of his own self TIL cells by means of an infusion, in combination with IL-2 treatment. The purpose of the IL-2 is to enhance the activity of the lymphocytes against the melanoma cells. Since the primary origin of the lymphocytes is from the patient himself, the body recognizes the cells as its own, and there is no problem of rejection. Therefore, the efficacy of the TIL cells is maintained even after the patient's immune system recovers. This treatment is still considered experimental, but to this day, over 30 patients have been treated at the Ella Institute using this method, and the results are encouraging. Initial results have been published in the following paper: